Open AccessCDX2 gene expression in acute lymphoblastic leukemia
Author(s) -
Hanaa H. Arnaoaut,
Doha A. Mokhtar,
Rania Mohamed Samy,
Sahar A. Khames,
Shereen A. Omar
Publication year - 2014
Publication title -
journal of egyptian national cancer institute/journal of the egyptian national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.398
H-Index - 22
eISSN - 2589-0409
pISSN - 1110-0362
DOI - 10.1016/j.jnci.2013.12.002
Subject(s) - cdx2 , minimal residual disease , medicine , gene , gene expression , lymphoblastic leukemia , clinical significance , acute leukemia , polymerase chain reaction , cancer research , haematopoiesis , reverse transcriptase , real time polymerase chain reaction , primer (cosmetics) , disease , leukemia , immunology , genetics , biology , stem cell , homeobox , chemistry , organic chemistry
CDX genes are classically known as regulators of axial elongation during early embryogenesis. An unsuspected role for CDX genes has been revealed during hematopoietic development. The CDX gene family member CDX2 belongs to the most frequent aberrantly expressed proto-oncogenes in human acute leukemias and is highly leukemogenic in experimental models. We used reversed transcriptase polymerase chain reaction (RT-PCR) to determine the expression level of CDX2 gene in 30 pediatric patients with acute lymphoblastic leukemia (ALL) at diagnosis and 30 healthy volunteers. ALL patients were followed up to detect minimal residual disease (MRD) on days 15 and 42 of induction. We found that CDX2 gene was expressed in 50% of patients and not expressed in controls. Associations between gene expression and different clinical and laboratory data of patients revealed no impact on different findings. With follow up, we could not confirm that CDX2 expression had a prognostic significance.